Stock analysts at StockNews.com began coverage on shares of Enzo Biochem (NYSE:ENZ - Get Free Report) in a research note issued to investors on Friday. The firm set a "hold" rating on the medical research company's stock.
Enzo Biochem Price Performance
Shares of ENZ traded down $0.10 during trading hours on Friday, hitting $1.04. The company had a trading volume of 137,893 shares, compared to its average volume of 98,613. The firm has a fifty day moving average price of $1.13 and a 200-day moving average price of $1.12. Enzo Biochem has a 52-week low of $0.99 and a 52-week high of $1.50.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in ENZ. XTX Topco Ltd grew its stake in shares of Enzo Biochem by 94.5% during the second quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company's stock valued at $31,000 after buying an additional 13,735 shares during the last quarter. BBR Partners LLC bought a new position in shares of Enzo Biochem during the third quarter valued at approximately $112,000. Finally, Renaissance Technologies LLC boosted its holdings in shares of Enzo Biochem by 2.6% in the second quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company's stock valued at $2,725,000 after purchasing an additional 64,417 shares during the period. 36.90% of the stock is owned by hedge funds and other institutional investors.
Enzo Biochem Company Profile
(
Get Free Report)
Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.
Recommended Stories
Before you consider Enzo Biochem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enzo Biochem wasn't on the list.
While Enzo Biochem currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for December 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
